2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2262

Evaluation of Illness Perception in Systemic Sclerosis Patients with Pulmonary Involvement
Abstract Number: 2094

Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination
Abstract Number: 1322

Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain
Abstract Number: 879

Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study
Abstract Number: 2064

Evaluation of Methods to Account for Differential Follow-up When Comparing Clinical Trial Data to Observational Data
Abstract Number: 354

Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis
Abstract Number: 2415

Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Abstract Number: 59

Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA
Abstract Number: 249

Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Abstract Number: 2249

Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment
Abstract Number: 1670

Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Abstract Number: 623

Evaluation of the Early Cervical Structural Changes in Patients with Non-Radiographic Axial Spondyloarthropathy
Abstract Number: 866

Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
Abstract Number: 681

Evaluation of the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population
Abstract Number: 2898

Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].